Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow39.88 M USD22.24 M USD18.82 M USD-5.15 M USD-2.58 M USD12.37 M USD15.83 M USD9.88 M USD10.80 M USD19.72 M USD11.44 M USD8.12 M USD
Depreciation & Amortization22.46 M USD24.20 M USD23.08 M USD22.44 M USD23.98 M USD20.71 M USD18.32 M USD18.09 M USD9.74 M USD8.38 M USD5.86 M USD6.03 M USD
Stock-Based Compensation24.39 M USD14.24 M USD14.42 M USD12.34 M USD10.71 M USD6.91 M USD8.80 M USD6.33 M USD6.92 M USD6.33 M USD5.09 M USD3.44 M USD
Capital Expenditures39.04 M USD11.19 M USD7.43 M USD9.02 M USD13.09 M USD7.33 M USD8.07 M USD5.79 M USD6.63 M USD6.20 M USD3.49 M USD4.31 M USD
Cash Flow from Investing-42.04 M USD-28.19 M USD-502000 USD-10.71 M USD5.66 M USD-73.13 M USD-23.94 M USD-6.71 M USD-170.99 M USD-73.85 M USD-4.49 M USD-5.35 M USD
Cash Flow from Financing11.28 M USD2.20 M USD865000 USD-1.64 M USD-12.22 M USD93.61 M USD-1.49 M USD-2.56 M USD143.25 M USD73.43 M USD-2.81 M USD-6.95 M USD
Dividends Paid3.41 M USD3.29 M USD
Stock Buybacks5.59 M USD
Free Cash Flow839000 USD11.05 M USD11.39 M USD-14.17 M USD-15.68 M USD5.04 M USD7.75 M USD4.09 M USD4.17 M USD13.52 M USD7.95 M USD3.81 M USD

Artivion Inc. is a medical device company focused on providing innovative technology solutions aimed at improving patient outcomes. Its primary function is to develop, manufacture, and sell devices associated with cardiac and vascular surgery, with a particular emphasis on cryopreservation and heart valve structures. The company's product portfolio serves critical areas such as aortic repair, heart valve therapy, and advanced cryogenic preservation techniques, underpinning its vital presence in the cardiovascular treatment sector. Its products are essential in supporting cardiac surgeons and healthcare professionals in utilizing life-saving technologies during complex medical procedures. Artivion Inc. serves a global market, impacting numerous aspects of healthcare by enabling the treatment of complex heart conditions and elevating surgical efficiency and efficacy. Headquartered in the United States, the company continues its commitment to innovation and quality in medical technology, playing a crucial role in advancing health outcomes and directly contributing to the fields of cardiovascular surgery and transplant medicine.